Experience
Dow Pharmaceutical Sciences, Inc.; Valeant
Taro Pharmaceuticals U.S.A., Inc.
Represents Dow and Valeant in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Onexton™.
Dow Pharmaceutical Sciences, Inc.; Valeant v. Taro Pharmaceuticals U.S.A., Inc., 2:16-cv-00217; 2:17-cv-00544, -01568, D.N.J., Judges Chesler, Waldor
Dow Pharmaceutical Sciences, Inc. v. Actavis, Inc.
Dow Pharmaceutical Sciences, Inc.
Dow Pharmaceutical Sciences, Inc. v. Tolmar, Inc.
Dow Pharmaceutical Sciences, Inc.
Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc.
Valeant; Salix; Progenics
Medicis Pharmaceutical Corp. v. Taro Pharmaceuticals USA, Inc.
Medicis Pharmaceutical Corp.
Valeant Pharmaceuticals North America, LLC v. Actavis, Inc.
Valeant Pharmaceuticals North America, LLC
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Finnegan secures 10 years of patent protection for Relistor®
Valeant; Salix; Progenics
Medicis Pharmaceutical Corp. v. Zydus Pharmaceuticals (USA) Inc.
Medicis Pharmaceutical Corp.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.